June 26, 2024 02:28 PM EDT
Pharma

Op­tum Rx may en­ter biosim­i­lar mar­ket to match com­peti­tors CVS, Ex­press Scripts

Katherine Lewin

News Reporter

Top PBM Op­tum Rx may be mov­ing in­to the biosim­i­lar busi­ness, join­ing its com­peti­tors CVS and Ex­press Scripts, ac­cord­ing to a US trade­mark ap­pli­ca­tion for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Supreme Court nar­row­ly re­jects Pur­due bank­rupt­cy plan, says it gives Sack­lers too much pro­tec­tion

GSK’s man­u­fac­tur­ing sites in Sin­ga­pore will use 100% re­new­able en­er­gy by 2025 

Bio­phar­ma lead­ers chart­ing a path for the in­dus­try's LGBTQ+ com­mu­ni­ty

A service from the Financial Times